Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,797 shares of the biopharmaceutical company’s stock after selling 3,112 shares during the period. Victory Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $9,365,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of ALNY. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth $33,000. True Wealth Design LLC grew its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 153 shares in the last quarter. Harvest Fund Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $45,000. Finally, Versant Capital Management Inc lifted its position in shares of Alnylam Pharmaceuticals by 77.6% during the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 83 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ALNY has been the subject of several recent analyst reports. Morgan Stanley lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Sanford C. Bernstein decreased their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $304.26.

Alnylam Pharmaceuticals Trading Down 0.3 %

Shares of Alnylam Pharmaceuticals stock opened at $241.75 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company’s 50-day simple moving average is $254.86 and its 200-day simple moving average is $260.57. The firm has a market cap of $31.30 billion, a price-to-earnings ratio of -111.41 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.